Results 171 to 180 of about 125,674 (260)

GPX1 confers resistance to metabolic stress in BCR/ABL-T315I mutant chronic myeloid leukemia cells. [PDF]

Cell Death Discov
Wang JD, Wang JX, Lin ZL, Xu N, Zhang L, Liu JJ, Gao R, Long ZJ.   +7 more
europepmc   +1 more source

A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA

Oncogene, 2014
G. Guo, Q. Kang, Xueliang Zhu, Xueliang Zhu, Qinghuang Chen, X. Wang, Yuhai Chen, Ouyang Jing, Lianfeng Zhang, H. Tan, Runsheng Chen, Shile Huang, Jilong Chen, Jilong Chen   +13 more
semanticscholar   +1 more source

Advances in Targeting BCR-ABL^T315I Mutation with Imatinib Derivatives and Hybrid Anti-Leukemic Molecules. [PDF]

Molecules
Tuzikiewicz A, Wawrzyniak W, Kutner A, Żołek T.   +3 more
europepmc   +1 more source

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status

Leukemia, 2014
Mathias Schmidt, J. Rinke, V. Schäfer, S. Schnittger, A. Kohlmann, E. Obstfelder, Christa Kunert, J. Ziermann, N. Winkelmann, E. Eigendorff, T. Haferlach, C. Haferlach, A. Hochhaus, T. Ernst   +13 more
semanticscholar   +1 more source

BCR-ABL tyrosine kinase [PDF]

Science-Business eXchange, 2011
openaire   +1 more source

Correction to "Molecular Modeling of Single- and Double-Hydrocarbon-Stapled Coiled-Coil Inhibitors against Bcr-Abl: Toward a Treatment Strategy for CML". [PDF]

J Phys Chem B
Carolina P Lima M, Hornsby BD, Lim CS, Cheatham TE.   +3 more
europepmc   +1 more source

A therapeutically targetable mechanism of BCR-ABL–independent imatinib resistance in chronic myeloid leukemia

Science Translational Medicine, 2014
Leyuan Ma, Y. Shan, R. Bai, Liting Xue, C. Eide, Jianhong Ou, L. Zhu, L. Hutchinson, J. Černý, H. Khoury, Z. Sheng, B. Druker, Shaoguang Li, Michael R. Green   +13 more
semanticscholar   +1 more source

[Allogeneic hematopoietic stem cell transplantation for the treatment of BCR::ABL-negative neutrophilic myeloid neoplasms: a clinical analysis of 12 cases]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Han TT, He Y, Liu J, Chen Y, Wang FR, Wang JZ, Chen YY, Fu HX, Xu LP, Zhang XH, Huang XJ, Wang Y.   +11 more
europepmc   +1 more source

Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity. [PDF]

J Enzyme Inhib Med Chem, 2023
El-Damasy AK, Jin H, Park JW, Kim HJ, Khojah H, Seo SH, Lee JH, Bang EK, Keum G.   +8 more
europepmc   +1 more source

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

Cancer, 2014
S. Soverini, C. De Benedittis, C. Papayannidis, S. Paolini, C. Venturi, I. Iacobucci, M. Luppi, P. Bresciani, M. Salvucci, D. Russo, S. Sica, E. Orlandi, T. Intermesoli, A. Gozzini, M. Bonifacio, G. Rigolin, F. Pane, M. Baccarani, M. Cavo, G. Martinelli   +19 more
semanticscholar   +1 more source